

INFORMATION

Renal Cancer Course

📅 22nd and 23rd May 2025

📍 **Sala de Actos Planta Baja**
Hospital General
Paseo Vall d'Hebron 119-129
Barcelona 08035


👤 **Coordination:**
Dra. Cristina Suárez
Senior Researcher of VHIO's
Genitourinary, Central Nervous System
(CNS) Tumors, Sarcoma and Cancer of
Unknown Primary Site Group

How to arrive:

🚇 **M L3 Vall d'Hebron** 🚌 **Lines 19 and 76**

Renal Cancer COURSE

22nd and 23rd May 2025



Organized by:



■ RENAL CANCER COURSE

22nd and 23rd May 2025

Day 1 | Thursday 22nd May

- 9:15-9:30 h • **Welcome and course objectives**
Cristina Suárez | Enrique Trilla | Joan Carles
- 9:30-11:00 h • **Chairs:** Joan Carles and Xavier Maldonado
Different techniques for localized treatment.
-**Surgery:** Enrique Trilla MD PhD
-**Ablative techniques:** David Lorente MD PhD
-**Radiotherapy:** Andre Geng MD
Neoadjuvant and adjuvant treatment. Rafael Morales MD
• **Q&A**
- 11:00-11:30 h • **Coffee Break**
- 11:30-12:40 h • **Chairs:** Rafael Morales and David Lorente
First line treatment in RCC. How to choose among different options? Nely M Díaz MD
Treatment of non-clear RCC. Cristina Suárez MD PhD
Role of nephrectomy in advanced disease. Enrique Trilla MD PhD
Predictive tissue biomarkers in RCC. Can they help in decision making? Ana Vivancos PhD
• **Q&A**
- 12:40-13:30 h • **Case presentation and discussion.** Joan Carles MD PhD and Marc Simó
Case 1: Managing adverse events. David Marmolejo MD
Case 2: PET imaging in RCC. Ignacio Navales MD
Cases presented by attendees
- 13:30-14:30 h • **Lunch**
- 14:30-16:00 h • **Chairs:** Enrique Trilla and Cristina Suárez
Role of the radiologist in metastatic disease and response evaluation. Richard Mast MD
The role of liquid biopsy in RCC, are we ready for it? Laia Catalan
Microbioma, where we are? Helena Palma
• **Q&A**

Day 2 | Friday 23rd May

- 8:00-9:00 h • **Multidisciplinary Tumor Board**
5th Floor General Hospital
- 9:30-11:00 h • **Chairs:** Joan Carles and Cristina Suárez
Role of metastasectomy in advanced disease, When and to whom? Nely M Díaz MD
Role of SBRT in advanced disease. Xavier Maldonado MD PhD
Second-line treatment in RCC and beyond. David Marmolejo MD
• **Q&A**
- 11:00-11:30 h • **Coffee Break**
- 11:30-12:45 h • **Chairs:** Xavier Maldonado and Enrique Trilla
Mechanism of resistance to IO. María Vieito MD
Teragnosis in RCC. Marc Simó MD
New drugs in RCC. Cristina Suárez MD PhD
• **Q&A**
- 12:45h-13:15 h • **Wrap-up and conclusions**
- 13:15h-14:00 h • **Lunch**
- 15:00-15:45 h • **Guided visit to CELLEX**

